Applications of Nefazodone Hydrochloride in Industrial Manufacturing

As an active manufacturer, we supply Nefazodone Hydrochloride for regulated pharmaceutical synthesis and contract development pipelines. This material has controlled and specialized uses within strictly compliant production streams. The following application scenarios reflect actual downstream segments engaged in regulated and quality-assured industrial operations.

1. API Formulation for Antidepressant Tablets

Pharmaceutical companies source Nefazodone Hydrochloride primarily for use as the active pharmaceutical ingredient (API) in oral solid dosage forms. During this stage, manufacturers adjust particle size distribution to enhance mixing with direct compression excipients, controlling moisture content and stability throughout the granulation and tableting processes. Full compliance with GMPs and regional pharmacopoeias is mandatory, with stringent in-process controls for assay, impurities, and uniformity. The finished antidepressant tablets target major depressive disorder indications and undergo batch release testing according to registered specifications before shipment.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP)
• European Pharmacopoeia (Ph. Eur.)
• China Pharmacopoeia (ChP)
• FDA cGMP 21 CFR Part 210/211

Typical usage ratio

• 15–25% by weight of total tablet formulation, depending on target dose strength
• Api-excipient ratio adjusted based on tablet size and required release profile

Downstream process integration

• Introduced during initial blending with diluents such as lactose or microcrystalline cellulose
• Wet granulation or direct compression based on flow properties
• Final blending with lubricants prior to tablet compression
• Coating post-compression for stability improvement

Final product types

• Nefazodone hydrochloride film-coated tablets
• Uncoated compressed tablets for oral administration

2. Reference Standard Manufacture for Analytical Laboratories

Chemical reference standard manufacturers request high-purity Nefazodone Hydrochloride from our production. Consistent characterization via NMR, IR, HPLC, and mass spectrometry supports traceability and batch reproducibility. Downstream laboratories use these authenticated standards for analytical method validation, stability testing, and impurity profiling of finished pharmaceuticals, following international laboratory quality systems and pharmacopoeial monograph specifications. Each lot enters a tightly controlled process with release documentation and COA.

Industry compliance standards

• ISO/IEC 17025 Laboratory Accreditation
• USP Reference Standards Program
• European Pharmacopoeia Reference Standards
• GMP for Pharmaceutical Reference Standards

Typical usage ratio

• 1–10 mg per analytical batch for calibration and system suitability
• Amount depends on required detection limits and analytical methodology

Downstream process integration

• Received in certified glass vials for direct weighing
• Diluted into solvent systems for HPLC/GC calibration
• Used in preparation of external standards and standard addition protocols

Final product types

• Nefazodone hydrochloride certified reference standard vials
• Secondary calibration solutions for method validation

3. Clinical Trial Material Synthesis for CRO/CMO Services

Specialized contract research and manufacturing organizations use Nefazodone Hydrochloride to prepare investigational medicinal products (IMPs) within Phase I–III clinical trial supplies. These facilities focus on flexible batch scaling, cryogenic storage, and serialized track-and-trace from raw material intake through semi-automated filling lines. QA/QC personnel implement detailed documentation, bridging data for regulatory submissions, and conduct real-time/release stability monitoring.

Industry compliance standards

• ICH Q10 Pharmaceutical Quality System
• EMA Guidelines for IMPs (EudraLex Volume 4, Annex 13)
• FDA Guidance for Industry – Investigational New Drug (IND) Applications
• GMP Annex 13 for Clinical Trial Materials

Typical usage ratio

• Active load tailored to clinical protocol: 50 mg to 400 mg per unit dose
• Actual raw material quantities scaled to meet clinical batch size

Downstream process integration

• Received under cold-chain or ambient logistics depending on stability
• Portioned into clinical packaging (blister packs, bottles)
• Kit assembly and double-blind randomization as required
• Samples retained for analytical/retrospective QC

Final product types

• Blinded clinical trial tablets/capsules
• Serialized investigational medicinal product kits

4. Impurity Profile Characterization in Pharmaceutical Quality Control

Pharmaceutical quality control laboratories utilize Nefazodone Hydrochloride to conduct forced degradation and stress testing studies. This enables accurate identification and quantification of degradation products and known impurities during method development and batch release. Reference-grade material supports robust specificity, recovery, and linearity validation under GMP environments, ensuring regulatory compliance for finished product impurity thresholds.

Industry compliance standards

• ICH Q3A/B Impurities in New Drug Substances/Products
• USP General <467>, <621> Chromatographic Methods
• FDA Guidance for Industry – Stability Testing
• GMP Laboratory Control Systems

Typical usage ratio

• 5–50 mg per stress test series, depending on analytical sensitivity
• Usage optimized for method calibration and limit validation

Downstream process integration

• Dissolved to prepare sample solutions for HPLC/UPLC analysis
• Exposed to hydrolytic, oxidative, photolytic, or thermal conditions
• Results documented in stability indicating method files

Final product types

• Validated analytical methods (SOPs, protocols)
• Impurity and degradation profile documentation